ImmPro Validates Drug Activity and Reveals Early Safety Concern

A research team investigating a therapy for treatment-resistant cancer turned to ImmPro after conventional proteomics failed to deliver clear answers. Using the ProteoSight™ platform, ImmPro confirmed that the drug engaged its intended target—and uncovered a previously undetected proteoform signal that raised questions about downstream effects and potential safety risks. This case study explores how intact proteoform analysis delivered the clarity needed to make confident development decisions—and surface insights peptide-based methods missed.

Download the full Case Study to see how ProteoSight™ delivers resolution.

*Access requires name, instituion, and email